3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Lung Neoplasms
4
Neoplasms
3
Breast Neoplasms
3
Ovarian Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Brain Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Neurofibromatoses
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Hydrocephalus
1
Headache
1
Gallbladder Neoplasms
1
Female Breast Carcinoma
1
Epilepsy
1
Disease Progression
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Brain Edema
1
Abdominal Neoplasms
1
Interventions
Capecitabine
3
Radiotherapy
2
Oxaliplatin
2
Fentanyl
2
Bupivacaine
2
udenafil
1
sodium phosphate
1
oxycodone-acetaminophen
1
XELOX
1
Tramadol
1
Sildenafil Citrate
1
Sevoflurane
1
Propofol
1
Pico-Salax
1
Orphenadrine
1
Neuroleptanalgesia
1
Morphine
1
Methadone
1
Lidocaine
1
Leucovorin
1
Ketorolac Tromethamine
1
Ketorolac
1
Ketamine
1
Irinotecan
1
Hydromorphone
1
Hydrocodone
1
Gabapentin
1
Fluorouracil
1
Ertapenem
1
Dexmedetomidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Rectal Neoplasms
×
Sevoflurane
×
Clear all
NCT01975064
2022-12-14
CAN
Uppsala University
Phase 4
Completed
5,774 enrolled